Compared to vehicle alone, signal changes were attenuated for many markers in the model for the erlotinib sensitive tumor (SERPINA3, β1,4-galactosyltransferase 1(B4GalT1), cystatin M, dihydrolipoamide dehydrogenase, mitochondrial (DLD), fibronectin fragment 3 (FN1.3), interleukin-15 receptor subunit alpha (IL-15 Ra), interleukin-8 (IL-8), kazal-type serine protease inhibitor domain-containing protein 1 (KAZD1), nucleoside-diphosphate kinase B (NDPK), plexin domain-containing protein 1 (PXDC1), protein S100-A6 (S100A6), and tenascin), but not for the resistant tumor (Supplementary Fig. S2). This evidence concerns the gene CST6 and neoplasm.